CollPlant Biotechnologies (NASDAQ:CLGN) Stock Rating Lowered by D. Boral Capital

CollPlant Biotechnologies (NASDAQ:CLGN) was downgraded by stock analysts at D. Boral Capital from a “buy” rating to a “hold” rating in a research report issued on Friday, MarketBeat Ratings reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $11.50.

CollPlant Biotechnologies Price Performance

NASDAQ:CLGN opened at $0.80 on Friday. CollPlant Biotechnologies has a one year low of $0.66 and a one year high of $4.98. The firm’s fifty day moving average price is $1.62 and its two-hundred day moving average price is $2.15. The company has a market cap of $10.22 million, a P/E ratio of -0.78 and a beta of 2.28.

CollPlant Biotechnologies (NASDAQ:CLGN) last posted its quarterly earnings results on Wednesday, November 26th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.65). CollPlant Biotechnologies had a negative return on equity of 102.00% and a negative net margin of 491.31%.The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $16.52 million. As a group, equities research analysts expect that CollPlant Biotechnologies will post -1.44 earnings per share for the current year.

Hedge Funds Weigh In On CollPlant Biotechnologies

A number of hedge funds have recently added to or reduced their stakes in CLGN. AMH Equity Ltd raised its stake in shares of CollPlant Biotechnologies by 28.7% in the second quarter. AMH Equity Ltd now owns 160,849 shares of the company’s stock worth $219,000 after purchasing an additional 35,849 shares during the last quarter. Villere ST Denis J & Co. LLC grew its holdings in CollPlant Biotechnologies by 13.0% during the second quarter. Villere ST Denis J & Co. LLC now owns 546,867 shares of the company’s stock worth $744,000 after buying an additional 63,000 shares in the last quarter. Finally, Pinnacle Associates Ltd. raised its position in CollPlant Biotechnologies by 9.9% in the 4th quarter. Pinnacle Associates Ltd. now owns 557,193 shares of the company’s stock valued at $780,000 after buying an additional 50,000 shares during the last quarter. Institutional investors and hedge funds own 21.69% of the company’s stock.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.